Antithrombotic Therapy in Heart Failure and Cardiomyopathy

摘要: Patients with heart failure and cardiomyopathy often present risk factors that may warrant anti-thrombotic therapy, such as atrial fibrillation, left ventricular thrombus, the presence of a hypercoagulable state. Decades clinical studies have provided wealth information speculations, but current role prophylactic antiplatelet anticoagulant therapies remained controversial. Post hoc analyses from large trials evidence warfarin use was associated improved outcomes despite lack significant reduction in thromboembolic risks. However, prospective randomized identified an unexpected benefit reduced hospitalizations those treated warfarin, which also be interpreted potential routine administration aspirin therapy. Ongoing provide necessary to guide future recommendations.